LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3. - Dataset (ID:20250)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | NVP-AEW541 | 3.33 | uM | LJP5 | 72 | hr | 1401 | 3835 | 4245 | 0.9076 | 0.8849 |
| SK-BR-3 | NVP-AEW541 | 10 | uM | LJP5 | 72 | hr | 1401 | 2434 | 4245 | 0.5755 | 0.4150 |
| SK-BR-3 | PHA-665752 | 0.04 | uM | LJP5 | 72 | hr | 1401 | 4135 | 4245 | 0.9757 | 0.9709 |
| SK-BR-3 | PHA-665752 | 0.12 | uM | LJP5 | 72 | hr | 1401 | 4358 | 4245 | 1.0277 | 1.0358 |
| SK-BR-3 | PHA-665752 | 0.37 | uM | LJP5 | 72 | hr | 1401 | 4193 | 4245 | 0.9908 | 0.9910 |
| SK-BR-3 | PHA-665752 | 1.11 | uM | LJP5 | 72 | hr | 1401 | 4388 | 4245 | 1.0329 | 1.0398 |
| SK-BR-3 | PHA-665752 | 3.33 | uM | LJP5 | 72 | hr | 1401 | 3932 | 4245 | 0.9269 | 0.9077 |
| SK-BR-3 | PHA-665752 | 10 | uM | LJP5 | 72 | hr | 1401 | 878 | 4245 | 0.2066 | -0.2588 |
| SK-BR-3 | PI103 | 0.04 | uM | LJP6 | 72 | hr | 1401 | 3693 | 4168 | 0.8855 | 0.8506 |
| SK-BR-3 | PI103 | 0.12 | uM | LJP6 | 72 | hr | 1401 | 2604 | 4168 | 0.6234 | 0.4773 |
| SK-BR-3 | PI103 | 0.37 | uM | LJP6 | 72 | hr | 1401 | 1778 | 4168 | 0.4263 | 0.1620 |
| SK-BR-3 | PI103 | 1.11 | uM | LJP6 | 72 | hr | 1401 | 1506 | 4168 | 0.3613 | 0.0463 |
| SK-BR-3 | PI103 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 1484 | 4168 | 0.3558 | 0.0349 |
| SK-BR-3 | PI103 | 10 | uM | LJP6 | 72 | hr | 1401 | 1348 | 4168 | 0.3236 | -0.0243 |
| SK-BR-3 | Dovitinib | 0.04 | uM | LJP5 | 72 | hr | 1401 | 3691 | 4245 | 0.8719 | 0.8370 |
| SK-BR-3 | Dovitinib | 0.12 | uM | LJP5 | 72 | hr | 1401 | 3385 | 4245 | 0.7973 | 0.7346 |
| SK-BR-3 | Dovitinib | 0.37 | uM | LJP5 | 72 | hr | 1401 | 2533 | 4245 | 0.5962 | 0.4453 |
| SK-BR-3 | Dovitinib | 1.11 | uM | LJP5 | 72 | hr | 1401 | 2363 | 4245 | 0.5554 | 0.3816 |
| SK-BR-3 | Dovitinib | 3.33 | uM | LJP5 | 72 | hr | 1401 | 2108 | 4245 | 0.4980 | 0.2920 |
| SK-BR-3 | Dovitinib | 10 | uM | LJP5 | 72 | hr | 1401 | 1873 | 4245 | 0.4404 | 0.1946 |
| SK-BR-3 | GSK 690693 | 0.04 | uM | LJP5 | 72 | hr | 1401 | 3111 | 4245 | 0.7340 | 0.6483 |
| SK-BR-3 | GSK 690693 | 0.12 | uM | LJP5 | 72 | hr | 1401 | 2932 | 4245 | 0.6890 | 0.5811 |
| SK-BR-3 | GSK 690693 | 0.37 | uM | LJP5 | 72 | hr | 1401 | 2938 | 4245 | 0.6969 | 0.5956 |
| SK-BR-3 | GSK 690693 | 1.11 | uM | LJP5 | 72 | hr | 1401 | 2923 | 4245 | 0.6895 | 0.5848 |
| SK-BR-3 | GSK 690693 | 3.33 | uM | LJP5 | 72 | hr | 1401 | 3080 | 4245 | 0.7259 | 0.6362 |